A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/pfizer-trial-backs-paxlovid-dose-high-risk-children-2026a1000lsp?src=rss
Author :
Publish date : 2026-06-26 12:33:00
Copyright for syndicated content belongs to the linked Source.